TYK Medicines Announces Positive Early Clinical Data for CDK Inhibitors at ESMO 2025

Reuters

Oct 21, 2025

TYK Medicines Announces Positive Early Clinical Data for CDK Inhibitors at ESMO 2025

TYK Medicines Inc. has announced positive early-phase clinical study results for three of its key cyclin-dependent kinase (CDK) inhibitor candidates: TYK-00540 (CDK2/4 inhibitor), TY-2699a (CDK7 inhibitor), and TY-302 (CDK4/6 inhibitor). The data were presented as posters at the European Society for Medical Oncology (ESMO) Congress 2025, held in Berlin, Germany from October 17 to 21, 2025. Among the findings, TYK-00540 demonstrated encouraging efficacy in patients with HR+/HER2- metastatic breast cancer who are resistant to CDK4/6 inhibitors, with manageable safety profiles observed. Ongoing studies include a combination trial of TYK-00540 with fulvestrant aimed at further addressing unmet clinical needs.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. TYK Medicines Inc. published the original content used to generate this news brief on October 21, 2025, and is solely responsible for the information contained therein.

At the request of the copyright holder, you need to log in to view this content

LOGIN / SIGN UP

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2577820680"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2577820680\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2577820680?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-10-21 20:15","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2577820680","market":"nz","top_or_hot":-1,"title":"TYK Medicines Announces Positive Early Clinical Data for CDK Inhibitors at ESMO 2025","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      TYK Medicines Announces Positive Early Clinical Data for CDK Inhibitors at ESMO 2025\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        TYK Medicines Inc. has announced positive early-phase clinical study results for three of its key cyclin-dependent kinase (CDK) inhibitor candidates: TYK-00540 (CDK2/4 inhibitor), TY-2699a (CDK7 inhibitor), and TY-302 (CDK4/6 inhibitor). The data were presented as posters at the European Society for Medical Oncology (ESMO) Congress 2025, held in Berlin, Germany from October 17 to 21, 2025. Among the findings, TYK-00540 demonstrated encouraging efficacy in patients with HR+/HER2- metastatic breast cancer who are resistant to CDK4/6 inhibitors, with manageable safety profiles observed. Ongoing studies include a combination trial of TYK-00540 with fulvestrant aimed at further addressing unmet clinical needs.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. TYK Medicines Inc. published the original content used to generate this news brief on October 21, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>TYK Medicines Announces Positive Early Clinical Data for CDK Inhibitors at ESMO 2025</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTYK Medicines Announces Positive Early Clinical Data for CDK Inhibitors at ESMO 2025\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-10-21 20:15</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      TYK Medicines Announces Positive Early Clinical Data for CDK Inhibitors at ESMO 2025\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        TYK Medicines Inc. has announced positive early-phase clinical study results for three of its key cyclin-dependent kinase (CDK) inhibitor candidates: TYK-00540 (CDK2/4 inhibitor), TY-2699a (CDK7 inhibitor), and TY-302 (CDK4/6 inhibitor). The data were presented as posters at the European Society for Medical Oncology (ESMO) Congress 2025, held in Berlin, Germany from October 17 to 21, 2025. Among the findings, TYK-00540 demonstrated encouraging efficacy in patients with HR+/HER2- metastatic breast cancer who are resistant to CDK4/6 inhibitors, with manageable safety profiles observed. Ongoing studies include a combination trial of TYK-00540 with fulvestrant aimed at further addressing unmet clinical needs.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. TYK Medicines Inc. published the original content used to generate this news brief on October 21, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02410","symbol_name":"同源康医药-B","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251021:nNDL7sF17S:1","article_id":"2577820680","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2577820680","pubTimestamp":1761048917,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"TYK Medicines Inc. has announced positive early-phase clinical study results for three of its key cyclin-dependent kinase  inhibitor candidates: TYK-00540 , TY-2699a , and TY-302 . The data were presented as posters at the European Society for Medical Oncology  Congress 2025, held in Berlin, Germany from October 17 to 21, 2025. Among the findings, TYK-00540 demonstrated encouraging efficacy in patients with HR+/HER2- metastatic breast cancer who are resistant to CDK4/6 inhibitors, with manageable safety profiles observed. Ongoing studies include a combination trial of TYK-00540 with fulvestrant aimed at further addressing unmet clinical needs.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. TYK Medicines Inc. published the original cont","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02410":"同源康医药-B","BK1161":"生物科技"},"translate_title":"TYK Medicines在ESMO 2025上公布CDK抑制剂积极的早期临床数据","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02410":0.9},"content_text":"TYK Medicines Announces Positive Early Clinical Data for CDK Inhibitors at ESMO 2025\n    \n\n        TYK Medicines Inc. has announced positive early-phase clinical study results for three of its key cyclin-dependent kinase (CDK) inhibitor candidates: TYK-00540 (CDK2/4 inhibitor), TY-2699a (CDK7 inhibitor), and TY-302 (CDK4/6 inhibitor). The data were presented as posters at the European Society for Medical Oncology (ESMO) Congress 2025, held in Berlin, Germany from October 17 to 21, 2025. Among the findings, TYK-00540 demonstrated encouraging efficacy in patients with HR+/HER2- metastatic breast cancer who are resistant to CDK4/6 inhibitors, with manageable safety profiles observed. Ongoing studies include a combination trial of TYK-00540 with fulvestrant aimed at further addressing unmet clinical needs.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. TYK Medicines Inc. published the original content used to generate this news brief on October 21, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}